P-392 Pemetrexed with or without a platinum compound in patients with malignant mesothelioma: A single institution “Expanded Access Program” experience

Lung Cancer ◽  
2005 ◽  
Vol 49 ◽  
pp. S218
Author(s):  
P. Baas ◽  
S. Burgers ◽  
J. Lieverst ◽  
O. Dalesio ◽  
N. van Zandwijk
Keyword(s):  
Malignant Mesothelioma ◽  
Platinum Compound ◽  
Single Institution ◽  
Expanded Access ◽  
Expanded Access Program ◽  
Access Program

scholarly journals Pemetrexed in the treatment of malignant mesothelioma: Results from an expanded access program in Germany

2010 ◽  
Vol 104 (1) ◽  
pp. 142-148 ◽  
Author(s):  
Martin Reck ◽  
Rolf A. Stahel ◽  
Joachim von Pawel ◽  
Meinolf Karthaus ◽  
Soenke Korfee ◽  
...  
Keyword(s):  
Malignant Mesothelioma ◽  
Expanded Access ◽  
Expanded Access Program ◽  
Access Program

Efficacy of nivolumab and ipilimumab (Nivo + Ipi) combination in melanoma patients (pts) treated at a single institution on an expanded-access program (EAP).

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 9554-9554 ◽  
Author(s):  
Alexander Noor Shoushtari ◽  
Pedram Navid-Azarbaijani ◽  
Claire Frances Friedman ◽  
Katherine Panageas ◽  
Michael Andrew Postow ◽  
...  
Keyword(s):  
Single Institution ◽  
Expanded Access ◽  
Expanded Access Program ◽  
Melanoma Patients ◽  
Access Program

A single-institution experience with the pembrolizumab (PEM) Expanded Access Program (EAP).

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e20088-e20088 ◽  
Author(s):  
Karen Mae Perdon ◽  
Dae Won Kim ◽  
Gener C Balmes ◽  
VanAnh Trinh ◽  
Susan E McIntyre ◽  
...  
Keyword(s):  
Single Institution ◽  
Expanded Access ◽  
Expanded Access Program ◽  
Access Program

Toxicity associated with ipilimumab and nivolumab (Ipi+Nivo) combination therapy in melanoma patients (pts) treated at a single-institution under an expanded-access program (EAP).

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 9519-9519 ◽  
Author(s):  
Claire Frances Friedman ◽  
Pedram Navid-Azarbaijani ◽  
Alexander Noor Shoushtari ◽  
Shonnette C. Campbell ◽  
Margaret K. Callahan ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Single Institution ◽  
Expanded Access ◽  
Expanded Access Program ◽  
Melanoma Patients ◽  
Access Program

IPILIMUMAB IN PATIENTS WITH DISSEMINATED MELANOMA: THE N.N. PETROV NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY EXPANDED ACCESS PROGRAM EXPERIENCE

2018 ◽  
Vol 64 (3) ◽  
pp. 388-393
Author(s):  
Yekaterina Anokhina ◽  
V. Rubinchik ◽  
Yekaterina Yaremenko ◽  
Gulfiya Teletaeva ◽  
Dilorom Latipova ◽  
...  
Keyword(s):  
Overall Survival ◽  
Adverse Events ◽  
Medical Research ◽  
Research Center ◽  
Expanded Access ◽  
Risk Of Death ◽  
National Medical ◽  
Expanded Access Program ◽  
Access Program

Ipilimumab (IPI) provides a ten-year overall survival in almost 20 % of selected patients participated in several phase II-III trials. However, the expanded access program (EAP) looks more like routine practice than like clinical trials& This is why the results of such application could be different. Here we present the long-term follow-up data of single center EAP. Ninety-six patients with disseminated melanoma progressing after at least one lines of drug therapy were included at the N.N. Petrov National Medical Research Center of Oncology. Sixty-seven (70 %) patients had stage IV M1c, 35 patients (36 %) had elevated LDH before initiating IPI therapy. All patients received IPI 3 mg / kg IV every 3 weeks for a maximum of 4 cycles. Totally, 320 cycles (mean - 3.3 per patient) were conducted. Grade 3-4 immuno-mediated adverse events (imAE) observed in 18 (19 %) patients. Three patients died of adverse events, possibly associated with ongoing therapy. The median time to progression was 3 (95 % CI, 2.4 to 3.5) mo., the median overall survival was 13 (95 % CI, 8.3 to17.6) mo. Previous immunotherapy with dendritic cell vaccines decreased the risk of death by 48 % (Log-rank p = 0.049). The wild type BRAF status increased three-year overall survival from 29 to 68 % (p = 0.042). Our data confirms long-term safety and efficacy of IPI in patients with pretreated disseminated melanoma in the close to real practice setting.

Sign in / Sign up

Export Citation Format

Share Document